11/15
Penn Medicine Study Describes Development of Personalized Cellular Therapy for Brain Cancer
Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, according to a study published in Science Translational Medicine by a team from the Perelman School of Medicine at the University of Pennsy
Penn Medicine Researchers Announce Latest Results of Investigational Cellular Therapy CTL019
The latest results of clinical trials of more than 125 patients testing an investigational personalized cellular therapy known as CTL019 will be presented by a University of Pennsylvania research team at the 56th American Society of Hematology Annual Meeting and Exposition.
Center for Advanced Cellular Therapeutics to Rise on Penn Medicine Campus
The University of Pennsylvania today reached an important milestone in its alliance with Novartis as it unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia.
Penn's Personalized Cellular Therapy for Leukemia Receives FDA's Breakthrough Therapy Designation
A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration’s Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL).
Penn Med Team Reports on Study of First 59 Leukemia Patients Who Received Personalized Cellular Therapy
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies.
Penn Medicine Study Examines Use of Yoga to Lessen Side Effects of Prostate Cancer Treatment
A new, first-of-its-kind study by researchers at the Perelman School of Medicine at the University of Pennsylvania seeks to learn whether men with prostate cancer who are undergoing radiation therapy can benefit from yoga.
Penn Study Reveals High Costs of Unnecessary Radiation for Terminal Cancer Patients
For cancer patients dealing with the pain of tumors that have spread to their bones, doctors typically recommend radiation as a palliative therapy.
Penn Medicine Study: Proton Therapy Cuts Side Effects for Pediatric Head and Neck Cancer Patients
The precise targeting and limited dosing of radiation via proton therapy is proving to be an advantage in ongoing efforts to reduce treatment side effects among head and neck cancer patients, according to a new study of pediatric patients from researchers at the Perelman School of Medicine at the University of Pennsylvania.
Penn Medicine Researchers Harness the Immune System to Fight Pancreatic Cancer
Pancreatic cancer ranks as the fourth-leading cause of cancer death in the United States, and is one of the most deadly forms of cancer, due to its resistance to standard treatments with chemotherapy and radiation therapy and frequently, its late stage at the time of diagnosis.
Penn Researchers Hornik and Lerman Receive $20 Million in Federal Funding to Establish Tobacco Center of Regulatory Science
A $20 million federal grant will create the University of Pennsylvania Tobacco Center of Regulatory Science (Penn TCORS). A first-of-its-kind regulatory science research enterprise, the new center is designed to conduct studies to inform the regulation of tobacco products to protect public health. The new grant is supported by the U.S.